+21%

est. 2Y upside i

HealthcareSeries B

Rank

#1588

Sector

HealthTech

Est. Liquidity

~3Y

Data Quality

Data: Medium

Archy offers moderate expected upside of 21% over 2 years, but high risk due to 44x revenue multiple and strong incumbents.

Last updated: July 19, 2026

Bull (20%)+116%

If Archy maintains high growth and IPO window opens, exit multiple could expand to 12x, yielding $471.6M exit (135.8% pre-dilution); net 115.8% after 20% dilution.

Base (45%)+27%

Exit multiple converges to comp average of 7.5x on $39.3M revenue, exit $294.8M (47.4% pre-dilution); net 27.4% after dilution.

Bear (35%)-41%

Growth disappoints, multiple compresses to 4x, exit $157.2M (-21.4% pre-dilution); net -41.4% after dilution; preference stack of $47M provides floor but exit above that.

Est. time to liquidity~3.0 years

Preference Stack Risk

moderate

Funding Intensity

24%

Total funding $47M equals 23.5% of $200M valuation, indicating moderate preference overhang.

Dilution Risk

moderate

With ~2 years runway, further dilution from Series C expected, reducing common equity by ~20%.

Secondary Liquidity

none

No secondary transactions reported; liquidity unlikely before exit.

Engineering — 6 roles

Sales — 4 roles

View all 10 open roles at Archy →

Last updated: February 22, 2026

Questions to Ask at the Interview

Strategic questions based on Archy's data — designed to show you've done your homework.

  • 1

    “How do you plan to displace entrenched incumbents like Dentrix?”

  • 2

    “What is the unit economics per dental practice and how does AI improve retention?”

  • 3

    “What is the current option pool and what percentage can I expect for my role?”

Community

Valuation Sentiment

Our model estimates +21% upside. What do you think?

Anonymous. Do not share material non-public information.

Community Discussion

Comments are reviewed before they appear publicly.

0/2000

Loading comments...

Disclaimer: This analysis is AI-generated and does not constitute financial or career advice. Always conduct your own due diligence.